Clinical trial
Effect of an Investigational Compound on Tolerability of Extended Release Niacin…
NCT00376584 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00376584 |
|---|---|
| Title | Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED) |
| Official title | A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Study to Evaluate the Efficacy of MK0524 to Improve Tolerability of Extended Release Niacin |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypercholesteremia, Hyperlipidemia |
| Intervention type | Drug |
| Interventions | MK-0524A, ER Niacin, Placebo |
| Enrollment | 825 |
| Start date | Jul 1, 2006 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Sep 15, 2006 |
| Last update posted | Feb 16, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: